

**Prior Authorization Criteria
Xolair® (omalizumab)**

Xolair® will only be prior authorized for patients who

- 1. are at least 12 years of age.**
- 2. have evidence of reversible airway disease (e.g., a greater than 12% improvement in FEV with at least a 200-ml increase or at least a 20% or greater improvement in PEF).**
- 3. must show evidence of inadequate control on inhaled steroids. (Provider must furnish documentation of inhaled steroid therapy, including dose and duration.)**
- 4. have an IgE level not less than 30 IU/ml nor more than the manufacturer's recommendation, based on weight. (The patient's weight and pre-treatment serum IgE must be presented to review dosing.)**

**Adopted 11/19/2003
Amended 2/10/2006**